163 related articles for article (PubMed ID: 38105655)
1. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.
Agrawal M; Richards W; Beaussant Y; Shnayder S; Ameli R; Roddy K; Stevens N; Richards B; Schor N; Honstein H; Jenkins B; Bates M; Thambi P
Cancer; 2024 Apr; 130(7):1137-1146. PubMed ID: 38105655
[TBL] [Abstract][Full Text] [Related]
2. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
3. HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.
Lewis BR; Garland EL; Byrne K; Durns T; Hendrick J; Beck A; Thielking P
J Pain Symptom Manage; 2023 Sep; 66(3):258-269. PubMed ID: 37302533
[TBL] [Abstract][Full Text] [Related]
4. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
Rosenblat JD; Meshkat S; Doyle Z; Kaczmarek E; Brudner RM; Kratiuk K; Mansur RB; Schulz-Quach C; Sethi R; Abate A; Ali S; Bawks J; Blainey MG; Brietzke E; Cronin V; Danilewitz J; Dhawan S; Di Fonzo A; Di Fonzo M; Drzadzewski P; Dunlop W; Fiszter H; Gomes FA; Grewal S; Leon-Carlyle M; McCallum M; Mofidi N; Offman H; Riva-Cambrin J; Schmidt J; Smolkin M; Quinn JM; Zumrova A; Marlborough M; McIntyre RS
Med; 2024 Mar; 5(3):190-200.e5. PubMed ID: 38359838
[TBL] [Abstract][Full Text] [Related]
5. Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.
Beaussant Y; Tarbi E; Nigam K; Miner S; Sager Z; Sanders JJ; Ljuslin M; Guérin B; Thambi P; Tulsky JA; Agrawal M
Cancer; 2024 Apr; 130(7):1147-1157. PubMed ID: 38105653
[TBL] [Abstract][Full Text] [Related]
6. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Raison CL; Sanacora G; Woolley J; Heinzerling K; Dunlop BW; Brown RT; Kakar R; Hassman M; Trivedi RP; Robison R; Gukasyan N; Nayak SM; Hu X; O'Donnell KC; Kelmendi B; Sloshower J; Penn AD; Bradley E; Kelly DF; Mletzko T; Nicholas CR; Hutson PR; Tarpley G; Utzinger M; Lenoch K; Warchol K; Gapasin T; Davis MC; Nelson-Douthit C; Wilson S; Brown C; Linton W; Ross S; Griffiths RR
JAMA; 2023 Sep; 330(9):843-853. PubMed ID: 37651119
[TBL] [Abstract][Full Text] [Related]
7. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; Carhart-Harris R; Cattell J; Daniel A; DeBattista C; Dunlop BW; Eisen K; Feifel D; Forbes M; Haumann HM; Hellerstein DJ; Hoppe AI; Husain MI; Jelen LA; Kamphuis J; Kawasaki J; Kelly JR; Key RE; Kishon R; Knatz Peck S; Knight G; Koolen MHB; Lean M; Licht RW; Maples-Keller JL; Mars J; Marwood L; McElhiney MC; Miller TL; Mirow A; Mistry S; Mletzko-Crowe T; Modlin LN; Nielsen RE; Nielson EM; Offerhaus SR; O'Keane V; Páleníček T; Printz D; Rademaker MC; van Reemst A; Reinholdt F; Repantis D; Rucker J; Rudow S; Ruffell S; Rush AJ; Schoevers RA; Seynaeve M; Shao S; Soares JC; Somers M; Stansfield SC; Sterling D; Strockis A; Tsai J; Visser L; Wahba M; Williams S; Young AH; Ywema P; Zisook S; Malievskaia E
N Engl J Med; 2022 Nov; 387(18):1637-1648. PubMed ID: 36322843
[TBL] [Abstract][Full Text] [Related]
8. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
10. Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
Anderson BT; Danforth A; Daroff PR; Stauffer C; Ekman E; Agin-Liebes G; Trope A; Boden MT; Dilley PJ; Mitchell J; Woolley J
EClinicalMedicine; 2020 Oct; 27():100538. PubMed ID: 33150319
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
[TBL] [Abstract][Full Text] [Related]
14. Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e121-e132. PubMed ID: 38518269
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial.
Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
JAMA Psychiatry; 2023 Dec; ():. PubMed ID: 38055270
[TBL] [Abstract][Full Text] [Related]
16. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
18. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Goodwin GM; Croal M; Feifel D; Kelly JR; Marwood L; Mistry S; O'Keane V; Peck SK; Simmons H; Sisa C; Stansfield SC; Tsai J; Williams S; Malievskaia E
Neuropsychopharmacology; 2023 Sep; 48(10):1492-1499. PubMed ID: 37443386
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
[TBL] [Abstract][Full Text] [Related]
20. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
